Metformin, the only recommended MATE1, MATE2-K, and OCT2 substrate for clinical DDI studies [2], is frequently prescribed (almost 80 million prescriptions in the USA in 2017 [81]) to treat type 2 diabetes mellitus. The gene discussed is SLC22A2; the disease is type 2 diabetes mellitus.